- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.04. | Psyence Biomedical doses first patient in psilocybin cancer trial | 2 | Investing.com | ||
| 23.04. | Psyence Biomedical startet Phase-IIb-Studie mit Psilocybin bei Krebspatienten | 2 | Investing.com Deutsch | ||
| 23.04. | Psyence Biomedical Ltd.: Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder | 216 | GlobeNewswire (Europe) | NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a clinical-stage biopharmaceutical company developing nature-derived psychedelic... ► Artikel lesen | |
| 20.04. | Psyence Biomedical Ltd.: Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source | 18 | GlobeNewswire (USA) | ||
| 17.04. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| PSYENCE BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 17.04. | Psyence Biomedical Stock Surges 42% On Growing Interest In Ibogaine Research | 3 | RTTNews | ||
| 17.04. | Psyence Biomedical Ltd.: Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine | 565 | GlobeNewswire (Europe) | NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a clinical-stage biopharmaceutical company advancing nature-derived psilocybin... ► Artikel lesen | |
| 17.04. | Morning Market Movers: Psyence Biomedical, WeShop, Julong Holding, Lifezone Metals See Big Swings | 629 | AFX News | BEIJING (dpa-AFX) - At 7:55 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 08.04. | Psyence Biomedical expands Australian clinical sites to five | 2 | Investing.com | ||
| 08.04. | Psyence Biomedical baut Studiennetzwerk in Australien aus | 3 | Investing.com Deutsch | ||
| 08.04. | Psyence Biomedical Ltd.: Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5-Supported Clinical Activities | 1 | GlobeNewswire (USA) | ||
| 11.03. | Psyence Biomedical Ltd.: Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone | 1 | GlobeNewswire (USA) | ||
| 03.03. | Psyence Biomedical Ltd.: Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial | 342 | GlobeNewswire (Europe) | NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine... ► Artikel lesen | |
| 02.03. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 20.02. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 20.02. | Psyence Biomedical Ltd.: Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment | 439 | GlobeNewswire (Europe) | NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine... ► Artikel lesen | |
| 17.02. | Psyence Biomedical Ltd.: Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders | 233 | GlobeNewswire (Europe) | NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine... ► Artikel lesen | |
| 14.02. | Psyence Biomedical Ltd.: Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway | 464 | GlobeNewswire (Europe) | NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine... ► Artikel lesen | |
| 12.02. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 11.02. | Psyence Biomedical-Aktie fällt nach Beilegung von Aktionärsstreit | 2 | Investing.com Deutsch |
1 2 3 Weiter >>
48 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 4,540 | -10,63 % | EQS-News: Evotec SE: Evotec gibt Ergebnisse für das erste Quartal 2026 bekannt: Transformation gewinnt an Dynamik | EQS-News: Evotec SE
/ Schlagwort(e): Quartalsergebnis/Quartals-/Zwischenmitteilung
Evotec gibt Ergebnisse für das erste Quartal 2026 bekannt: Transformation gewinnt an Dynamik... ► Artikel lesen | |
| MODERNA | 43,090 | -5,01 % | Moderna: Hantavirus-Schlagzeilen treiben Impfstoff-Aktie an | Das Hantavirus ist auf einem kleinen Kreuzfahrtschiff im Atlantik ausgebrochen. Die Weltgesundheitsorganisation (WHO) hat inzwischen fünf von acht Verdachtsfällen als offizielle Fälle bestätigt. Aus... ► Artikel lesen | |
| VALNEVA | 2,540 | -1,01 % | Valneva-Aktie vor Zahlen: Was ist am 13. Mai zu erwarten? | Die Aktie von Valneva bleibt auch nach der jüngsten Kapitalspritze unter Druck. Nachdem bereits in unserem vorherigen Artikel auf die begrenzten Erholungschancen hingewiesen wurde, bestätigt die aktuelle... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 19,000 | -3,55 % | Palatin Technologies: Lizenzvereinbarung treibt Umsatz im dritten Quartal an und beflügelt die Aktie | ||
| VIVOSIM LABS | 1,290 | -0,77 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,126 | 0,00 % | XFRA GBY: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSANGAMO THERAP.INC.DL-... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 12,360 | +3,69 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates | Presented positive Phase 3 HAELO topline clinical data for lonvo-z in HAE; initiated rolling BLA submission; anticipate U.S. launch in first half of 2027Recently resumed patient screening in MAGNITUDE... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,650 | -1,08 % | Arbutus Biopharma Corporation: Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update | Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities... ► Artikel lesen | |
| XOMA ROYALTY | 35,200 | -1,12 % | XOMA Royalty Corp - 10-Q, Quarterly Report | ||
| CELLECTAR BIOSCIENCES | 2,930 | +0,34 % | Cellectar Biosciences Q1 2026 Earnings Preview | ||
| AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech raises $4.2M through warrant exercise deal | ||
| NOVOCURE | 15,735 | +0,90 % | Novocure Reports First Quarter 2026 Financial Results | Quarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio
Optune Pax approved by the U.S. FDA and launched for the treatment of locally advanced pancreatic... ► Artikel lesen | |
| PHARMING | 1,137 | +1,84 % | Pharming Group N.V.: Pharming Group reports first quarter 2026 financial results; on track for Joenja U.S. pediatric label expansion and launches in Japan and Europe in 2026 | First quarter 2026 total revenues were US$72.4 million, an 8% decrease compared to the first quarter 2025RUCONEST revenue was US$58.4 million, a 15% decrease compared to the first quarter 2025, mainly... ► Artikel lesen | |
| TRAWS PHARMA | 1,750 | +4,17 % | Traws Pharma, Inc.: Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections | NEWTOWN, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to... ► Artikel lesen | |
| MOLECULIN BIOTECH | 2,120 | -9,40 % | Moleculin Biotech, Inc.: Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits | Pooled analysis of 90 subjects across 5 trials shows stable mean ejection fraction and no clinically significant left ventricular dysfunction Data demonstrates Annamycin addresses the principal barrier... ► Artikel lesen |
PSYENCE BIOMEDICAL LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -8,08 % bei einem Aktienkurs von 5,120 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PSYENCE BIOMEDICAL LTD finden Sie auf Wallstreet Online.